Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

992 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A first radiotherapy application of functional bulboclitoris anatomy, a novel female sexual organ-at-risk, and organ-sparing feasibility study.
Marshall DC, Ghiassi-Nejad Z, Powers A, Reidenberg JS, Argiriadi P, Ru M, Dumane V, Buckstein M, Goodman K, Blank SV, Schnur J, Rosenstein B. Marshall DC, et al. Among authors: powers a. Br J Radiol. 2021 Aug 1;94(1124):20201139. doi: 10.1259/bjr.20201139. Epub 2021 Jun 30. Br J Radiol. 2021. PMID: 34192475 Free PMC article.
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Do KT, Kochupurakkal B, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB, D'Andrea AD, Shapiro GI. Do KT, et al. Among authors: powers a. Clin Cancer Res. 2021 Sep 1;27(17):4710-4716. doi: 10.1158/1078-0432.CCR-21-1279. Epub 2021 Jun 15. Clin Cancer Res. 2021. PMID: 34131002 Clinical Trial.
Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors.
Do KT, Manuszak C, Thrash E, Giobbie-Hurder A, Hu J, Kelland S, Powers A, de Jonge A, Shapiro GI, Severgnini M. Do KT, et al. Among authors: powers a. Cancer Immunol Immunother. 2021 Oct;70(10):2991-3000. doi: 10.1007/s00262-021-02910-x. Epub 2021 Mar 20. Cancer Immunol Immunother. 2021. PMID: 33745032 Free PMC article.
A non-canonical mechanism of GPCR activation.
Powers AS, Khan A, Paggi JM, Latorraca NR, Souza S, Di Salvo J, Lu J, Soisson SM, Johnston JM, Weinglass AB, Dror RO. Powers AS, et al. Nat Commun. 2024 Nov 16;15(1):9938. doi: 10.1038/s41467-024-54103-6. Nat Commun. 2024. PMID: 39550377 Free PMC article.
Disentangling sex differences in PTSD risk factors.
Haering S, Seligowski AV, Linnstaedt SD, Michopoulos V, House SL, Beaudoin FL, An X, Neylan TC, Clifford GD, Germine LT, Rauch SL, Haran JP, Storrow AB, Lewandowski C, Musey PI Jr, Hendry PL, Sheikh S, Jones CW, Punches BE, Swor RA, Gentile NT, Hudak LA, Pascual JL, Seamon MJ, Pearson C, Peak DA, Merchant RC, Domeier RM, Rathlev NK, O'Neil BJ, Sanchez LD, Bruce SE, Harte SE, McLean SA, Kessler RC, Koenen KC, Powers A, Stevens JS. Haering S, et al. Among authors: powers a. Nat Ment Health. 2024 May;2(5):605-615. doi: 10.1038/s44220-024-00236-y. Epub 2024 Apr 19. Nat Ment Health. 2024. PMID: 39534178 Free PMC article.
992 results